Sjögren's Syndrome is an autoimmune disease in which the body's immune system erroneously attacks the tear and salivary glands, causing severe dry eyes and dry mouth.
Due to impaired tear and saliva production, patients experience not only oral pruritus and discomfort but also visual impairment and an increased risk of dental caries and infections. As the disease progresses, patients also manifest systemic symptoms such as arthralgia and extreme fatigue, which significantly diminishes their quality of life.
Presently, no treatment offers a fundamental cure for immune disorders, and current therapy focuses on symptomatic management. For example, patients with Sjögren's syndrome receive the following treatments:
- Dry eye management strategy: Artificial tears and lubricating eye ointment
- Xerostomia management strategies include: Frequent sips of water, salivary gland massage, artificial saliva substitutes (sprays/gels), and oral secretagogues (e.g., pilocarpine).
- Systemic therapy for symptoms includes: Anti-inflammatory medications such as antirheumatic drugs, steroids, immunosuppressants, and biologic agents (e.g., rituximab), depending on the symptoms and severity.
However, these treatments have certain limitations.
Artificial tears and saliva provide only temporary hydration and are ineffective against the underlying immune disorder, necessitating frequent reapplication. Salivary secretagogues also do not fully alleviate symptoms and cannot halt the progression of the disease itself.
Immunosuppressants and steroids can help alleviate systemic inflammation; however, concerns exist regarding long-term use increasing the risk of side effects such as infection, osteoporosis, and diabetes. Furthermore, these medications often do not fully ameliorate the dryness symptoms themselves, and many patients express dissatisfaction with their efficacy.
Therefore, there remains a significant unmet medical need for the treatment of the underlying cause of Sjögren's Syndrome.
Sjögren's Syndrome and Stem Cell Therapy: New Possibilities in Regenerative Medicine
In light of the current situation, new approaches within the field of regenerative medicine have recently garnered renewed attention. One such approach is "stem cell therapy."
Stem cells are specialized cells with the ability to differentiate into various cell types and the capacity to repair damaged tissues. Among these, mesenchymal stem cells (MSCs) are being investigated as a promising cell type for the treatment of autoimmune diseases.
MSCs can be harvested from various sources, such as bone marrow, adipose tissue, and umbilical cord, and can be cultured and expanded for use in patient treatment. In fact, therapeutic research utilizing MSCs for chronic diseases, including Sjögren's Syndrome, is being conducted worldwide, and has demonstrated the potential to "alleviate dryness."
Current experimental and clinical research reports that stem cell therapy restores lacrimal and salivary secretory function in Sjögren's Syndrome animal models and patients, and reduces inflammatory cell infiltration in the salivary glands.
This represents a unique benefit of regenerative medicine, not possessed by conventional symptomatic therapies.
Advantages of stem cells derived from Wharton's Jelly (WJ-MSC):
There are several types of stem cells depending on their source; however, those that have recently received particular attention are mesenchymal stem cells derived from Wharton's Jelly, which is contained within the umbilical cord.
Stem cells derived from Wharton's Jelly are immature cells that can be painlessly harvested from umbilical cord tissue obtained at birth, and are reported to possess high proliferative capacity and immunomodulatory capabilities.
Originating from newborn infant cells, these are characterized as "young and healthy cells," and even when donor cells are directly transferred to another patient, immunological rejection is rarely observed. This unique immunological property is attributed to protecting the fetus from maternal immunity, and cells derived from the umbilical cord and placenta are believed to contain numerous intrinsic immunosuppressive substances.
Therefore, stem cells derived from Wharton's Jelly...
In stem cell therapy research, while stem cells derived from bone marrow and adipose tissue are also utilized, umbilical cord-derived stem cells offer significant advantages in terms of ease of collection and minimal donor burden.
In this way, stem cell therapy is anticipated as a novel treatment strategy offering hope to patients with Sjögren's Syndrome. While currently still in the research phase, its gradually emerging effects and mechanisms will be examined in more detail below.
Mechanism of Action of Stem Cell Therapy for Sjögren's Syndrome
Why is Sjögren's Syndrome exacerbated by stem cells?
The key lies in the immunomodulatory capabilities and tissue regeneration-promoting effects of mesenchymal stem cells. In Sjögren's Syndrome, analogous to a vehicle with malfunctioning brakes, the immune system becomes dysregulated and attacks the body's own lacrimal and salivary glands.
Stem cell therapy functions to modulate a hyperactive immune system. Specifically, the diverse substances secreted by stem cells (cytokines and growth factors, collectively referred to as the "secretome") act on immune cells, thereby attenuating excessive inflammatory responses.
It has been confirmed that anti-inflammatory cytokines released by stem cells reduce the production of pro-inflammatory mediators (such as TNF-α and IL-17) and increase anti-inflammatory mediators (such as IL-10).
In this way, the autoimmune reactions that have damaged the lacrimal and salivary glands are mitigated.
Furthermore, mesenchymal stem cells also possess the ability to facilitate the repair of damaged tissues. These stem cells accumulate in damaged lacrimal and salivary gland tissues, where they then promote tissue regeneration.
While stem cells themselves can differentiate and generate new cells, their more significant role lies in their supportive effect on surrounding tissues through the secretion of growth factors and angiogenic factors. For instance, much like providing fertilizer and water to a drought-stricken field, stem cells deliver essential nutrients and signals to damaged areas to promote the cells' intrinsic self-repair mechanisms.
This method is anticipated to restore the function of damaged glandular tissue, specifically the ability to produce tears and saliva. Additionally, MSCs possess properties that suppress tissue fibrosis (hardening) and promote new capillary formation, thereby enhancing the glandular tissue microenvironment and facilitating moisture production.
Furthermore, mesenchymal stem cells also enhance immune components that are not readily augmented by other therapies. For example, studies report that MSC administration increases immune-suppressive regulatory T cells (Tregs) and reduces pro-inflammatory Th17 cells. By thus shifting the immune balance towards normalization, the disruption of the autoimmune vicious cycle can be anticipated.
Stem cell therapy not only offers transient symptomatic relief but also operates through a dual mechanism: by modulating immune dysregulation and simultaneously promoting the regeneration of damaged tissue. This comprehensive approach positions it as a fundamental therapeutic solution for Sjögren's Syndrome.
Evidence of Stem Cell Therapy Effectiveness for Sjögren's Syndrome
What is the efficacy of stem cell therapy? Small-scale clinical studies and clinical trial reports have been conducted globally, with the majority reporting promising results.
Restoration of secretory function
It has been confirmed that stem cell therapy enhances the secretion volume of tears and saliva. Specifically, in a clinical trial for Sjögren's Syndrome conducted in China, at 3 months post-treatment, the secretory function of the salivary and lacrimal glands significantly improved compared to the placebo group. In another study involving intravenous administration of MSCs, many patients experienced an increase in saliva production. Furthermore, regarding dry eyes, it was reported that tear secretion tended to increase, facilitating the alleviation of both dry eye and dry mouth symptoms.
Alleviate symptoms
Patients receiving stem cell therapy reported improvement in subjective symptoms, including systemic fatigue and joint pain, as well as dryness.
In fact, the patient symptom evaluation score (an index called ESSPRI) significantly increased in the treatment group compared to the placebo group, indicating an improvement in quality of life, including a reduction in pain and fatigue.
Decrease in disease activity
Increases in indicators reflecting Sjögren's disease activity (ESSDAI score) have also been reported. For instance, in one clinical study, following MSC treatment, disease activity scores significantly decreased. Three months post-treatment, 46% of patients demonstrated a 30% or greater improvement in their disease. This proportion increased to 71% at 6 months and 83% at 1 year, with all these percentages reflecting a significant improvement of 30% or more.
A trend of increasing effectiveness over time was also confirmed, and significant expectations are held for the sustained efficacy of stem cell therapy. Indeed, in a separate trial in China, ESSDAI scores significantly decreased for up to 6 months post-treatment. Furthermore, indicators of systemic inflammation (ESR, erythrocyte sedimentation rate) and patient functional assessments (ESSPRI) also improved, demonstrating that stem cell therapy suppresses disease activity.
Correction of immune disorders
Furthermore, data indicates that stem cell therapy reduces autoantibodies and inflammatory substances characteristic of Sjögren's Syndrome.
For instance, it has been reported that blood concentrations of anti-SSA/Ro and anti-SSB/La autoantibodies decreased in some treated patients, indicating an improvement in markers of immune dysfunction. Furthermore, in previous clinical trials, the stem cell therapy group showed a reduction in elevated immunoglobulins such as IgG and IgM. This suggests that excessive autoimmune reactions in the body have subsided, providing evidence that stem cell therapy ameliorates the underlying pathophysiology of Sjögren's Syndrome itself. Moreover, tissue biopsy findings revealed that, following stem cell therapy, lymphocytic infiltration (inflammatory cell infiltration) in the salivary glands was significantly reduced.
In this regard, considering multi-faceted indicators, MSC stem cell therapy demonstrates promising efficacy for Sjögren's Syndrome. While much of this evidence is still in the research phase, it continues to accumulate globally. Notably, the significant improvement in clinical symptoms and test parameters observed with treatments exhibiting a high safety profile is highly encouraging news for patients.
Stem cell therapy is beginning to demonstrate the potential to provide fundamental effects that are unattainable through symptomatic treatment alone for the long-standing challenge of dryness symptoms in Sjögren's Syndrome.
Safety of Stem Cell Therapy for Sjögren's Syndrome and Side Effects
In general, adverse effects associated with stem cell therapy are mild and transient.
Upon administration of intravenous infusions, mild transient fever, headache, or fatigue are infrequently reported. These manifestations typically resolve rapidly and do not result in long-term sequelae.
Reports from clinical trials also indicate that among 64 patients who received the treatment, only 2 experienced transient pruritus, and no other adverse events were observed. Consequently, stem cell therapy is considered a treatment with an exceptionally high safety profile.
Furthermore, stem cells primarily modulate immunity, unlike steroid medications which cause severe immunosuppression. Consequently, an increased risk of infection is not anticipated. In fact, there have been no reports of severe infections associated with stem cell therapy. On the contrary, there are instances where MSCs have been applied in difficult-to-treat infections (e.g., MSC administration for severe GVHD alongside other therapies).
Furthermore, stem cell therapy obviates the need for high-dose chemotherapy or prior general anesthesia, unlike bone marrow transplantation, thereby alleviating the physical burden on patients. Therefore, stem cell therapy for Sjögren's syndrome can be considered a highly safe treatment option with minimal concerns regarding adverse effects.
In conclusion, the encouraging safety profile observed in research to date is a significant reason for optimism regarding stem cell therapies. Current studies report virtually no serious side effects. Furthermore, even among more than 400 patients with autoimmune diseases treated with mesenchymal stem cells, the incidence of serious treatment-related adverse events was very low, demonstrating a high safety profile.
Conclusion
For Sjögren's Syndrome patients, "living without dryness" is a powerful aspiration. Advances in stem cell therapy and regenerative medicine are beginning to offer promise for what was previously an elusive hope.
Stem cell therapy is a a novel approach aimed at fundamentally improving Sjögren's Syndrome by modulating the overactive immune system and repairing damaged tissues.
Ongoing research findings are progressively revealing significant symptomatic improvements and a high safety profile, with accumulating evidence offering hope to patients. Naturally, stem cell therapy has not yet been established as a standard treatment, and further research and verification are ongoing. However, for patients who are anxious that current treatments offer no further benefit, stem cell therapy may present a new option.
Given its effectiveness and safety, there is also a possibility that in the future, stem cell therapy will be widely adopted as one of the standard treatments for Sjögren's Syndrome. Crucially, the concept of stem cell therapy aims to unlock the patient's own intrinsic healing power, which is its appeal as a body-friendly treatment.
Bringing an end to days disrupted by persistent dryness, and restoring essential moisture and comfort, stem cell therapy represents an innovative treatment that offers peace of mind and renewed hope to patients battling Sjögren's Syndrome.
If you have any questions or concerns, please do not hesitate to consult with a specialized medical institution. We are always committed to supporting your optimal future based on the latest knowledge.